The future of small molecule inhibitors in lymphoma
- PMID: 19679013
- DOI: 10.1007/s11912-009-0051-1
The future of small molecule inhibitors in lymphoma
Abstract
For the many patients with lymphoma that has relapsed after and/or has become refractory to existing treatments, the development of novel therapeutics is imperative. Investigation into intracellular processes that are dysregulated during lymphomagenesis has uncovered several new potential targets for anticancer agents. Although monoclonal antibodies and other immunotherapeutics have led to dramatic advances in the treatment of patients with lymphoma, the parallel development of small molecule inhibitors has been equally exciting. These agents, whose small size allows direct entry into tumor cells, can target distinct proteins or complexes, thereby disrupting molecular processes on which neoplastic cells depend for survival and growth. This review surveys the published literature on many of these new targeted molecules, focusing on some of the most promising agents for which phase 2 data currently exist. It also explores the potential for incorporating these agents into broader multidrug regimens.
Similar articles
-
The role of bortezomib in the treatment of lymphoma.Cancer Invest. 2007 Dec;25(8):766-75. doi: 10.1080/07357900701579570. Cancer Invest. 2007. PMID: 18058474 Review.
-
Discovery, Development, and clinical applications of bortezomib.Oncology (Williston Park). 2004 Dec;18(14 Suppl 11):4-13. Oncology (Williston Park). 2004. PMID: 15688597 Review.
-
Targeted therapy in lymphoma.J Hematol Oncol. 2010 Nov 23;3:45. doi: 10.1186/1756-8722-3-45. J Hematol Oncol. 2010. PMID: 21092307 Free PMC article. Review.
-
Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.Int J Cancer. 2006 Sep 1;119(5):971-9. doi: 10.1002/ijc.21805. Int J Cancer. 2006. PMID: 16557600 Review.
-
The development of proteasome inhibitors as anticancer drugs.Cancer Cell. 2004 May;5(5):417-21. doi: 10.1016/s1535-6108(04)00120-5. Cancer Cell. 2004. PMID: 15144949 Review.
Cited by
-
Novel therapeutics for aggressive non-Hodgkin's lymphoma.J Clin Oncol. 2011 May 10;29(14):1876-84. doi: 10.1200/JCO.2010.32.7171. Epub 2011 Apr 11. J Clin Oncol. 2011. PMID: 21483007 Free PMC article. Review.
-
Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas.Front Oncol. 2019 Jun 4;9:443. doi: 10.3389/fonc.2019.00443. eCollection 2019. Front Oncol. 2019. PMID: 31214498 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical